CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Analyst Earnings Estimates
NYSEARCA:CANF - American Stock Exchange - US13471N3008 - ADR
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 853K 11.80% | 810K -5.04% | 743K -8.27% | 3.786M 409.56% | 3.786M | 3.004M -20.66% | |
| EBITDA YoY % growth | -12.828M 9.20% | -10.082M 21.41% | -8.18M 18.87% | N/A | N/A | N/A | |
| EBIT YoY % growth | -12.842M 9.17% | -10.096M 21.38% | -8.195M 18.83% | -35.207M -329.62% | -40.886M -16.13% | -32.762M 19.87% | |
| Operating Margin | -1,505.51% | -1,246.42% | -1,102.96% | -929.93% | -1,079.92% | -1,090.60% | |
| EPS YoY % growth | N/A | N/A | N/A | -1,782.33 -1.01% | -1,533.63 13.95% | -2,740.81 -78.71% |
All data in USD
| Q3 / 24 | Q4 / 24 | |
|---|---|---|
| EPS Q2Q % growth | -481.27 | -481.27 -3,370.23% |
| Revenue Q2Q % growth | 567.865K -22.53% | 567.865K -3.91% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -9.086M -387.17% | -10.6M -477.97% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2023 Q2Q % growth | -13.87 | -361.63 | 347.76 | 96.16% |
| Q3 2023 Q2Q % growth | 0.00 100.00% | -644.74 | 644.74 | 100.00% |
| Q2 2023 Q2Q % growth | 0.00 100.00% | -583.70 | 583.70 | 100.00% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 316K -55.80% | 567.865K | -251.865K | -44.35% |
| Q1 2024 Q2Q % growth | 189.73% | 567.865K | % | |
| Q4 2023 Q2Q % growth | 591K 200.00% | 414.304K | 176.696K | 42.65% |
| Q3 2023 Q2Q % growth | 733K 259.31% | 414.304K | 318.696K | 76.92% |
| Q2 2023 Q2Q % growth | 715K 250.49% | 370.015K | 344.985K | 93.24% |
| Q1 2023 Q2Q % growth | 196K -4.39% | % | ||
| Q4 2022 Q2Q % growth | 197K -3.43% | % | ||
| Q3 2022 Q2Q % growth | 204K -18.73% | % | ||
| Q2 2022 Q2Q % growth | 204K -18.40% | % | ||
| Q1 2022 Q2Q % growth | 205K 38.51% | % | ||
| Q4 2021 Q2Q % growth | 204K 36.00% | % | ||
| Q3 2021 Q2Q % growth | 251K 18.96% | % | ||
| Q2 2021 Q2Q % growth | 250K -37.81% | % | ||
| Q1 2021 Q2Q % growth | 148K -25.25% | % | ||
| Q4 2020 Q2Q % growth | 150K -21.88% | % | ||
| Q3 2020 Q2Q % growth | 211K -81.68% | % | ||
| Q2 2020 Q2Q % growth | 402K 3.34% | % | ||
| Q1 2020 Q2Q % growth | 198K -33.78% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 11.84% |
| Revenue | 0% | 0% | 0% | 11.52% |